Protocol for the "SlowSpeed" trials has been published; 3 trials examining the feasibility & preliminary efficacy of a gamified, remotely administered exercise intervention vs. active control over 18–36 months in complementary prodromal #Parkinsons groups www.nature.com/articles/s41...

A critical appraisal of glymphatic dysfunction in #Alzheimers; "Clearly defining what is & is not currently understood about the role that glymphatic dysfunction plays in the development of AD" www.science.org/doi/10.1126/...

Alterity Therapeutics announces that the US FDA has agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of Multiple System Atrophy; On track to initiate by year-end 2026 alteritytx.com/announcement...

Researchers introduce EmulatRx, an agentic framework that derives real-world evidence to facilitate & accelerating the clinical trial design process; It was applied to data from both acute diseases & chronic diseases ( #Alzheimers & #Parkinsons) www.nature.com/articles/s41...

New research examined the evolutionary history of #Parkinsons-associated LRRK2 & PRKN in primates & human populations, finding evidence of positive selection on both genes; LRRK2 G2019S rose in neolithic era due to ancient infectious pressures (Salmonella) www.nature.com/articles/s41...

A preprint of the results of the 52-week Phase 2 ambitious clinical trial of ambroxol in 65 people with GBA1-associated #Parkinsons has been made available; Treatment was safe/tolerable, but showed no disease-modifying benefit versus placebo papers.ssrn.com/sol3/papers....

My weekend reading: Impressive, wide-ranging review of recent advances in #Alzheimers research - from molecular mechanisms to therapeutic strategies; Just in time for the #AAIC2026 meeting www.cell.com/cell/fulltex...

New research "presents a human isogenic induced pluripotent stem cell–derived dopaminergic neuron model that faithfully recapitulates the diverse biochem., morphol., & ultrastructural features of Lewy Body neuropath." www.science.org/doi/10.1126/...

"No serious adverse events were attributed to the cell product, no graft-induced dyskinesias were observed and serial magnetic resonance imaging showed no evidence of tumor formation"; 6/7 patients reduced medication at 12-months (15.6%⬇️ in low-dose cohort & 27.5% in high-dose)

New paper presents the 12-month primary safety end point & interim efficacy outcomes from the Phase 1/2, open-label trial evaluating STEM-PD (a dopaminergic progenitor product derived from human pluripotent stem cells) www.nature.com/articles/s41...

Kenai Therapeutics announces the completion of enrollment for the REPLACE Phase 1b/2a clinical trial of RNDP-001, an investigational cell therapy being developed for the treatment of moderate to moderate-severe idiopathic #Parkinsons www.kenaitx.com/press-releas...

Researchers present 5-year safety/tolerability results from open-label, phase 1 study of bilateral putaminal delivery of AAV2-GDNF in 13 people with advanced #Parkinsons; "Clinical measures did not change sig. btwn baseline & final follow-up" movementdisorders.onlinelibrary.wiley.com/doi/10.1002/...

Initial results from the Syntara & Parkinson's UK Phase 2 study of SNT-4728 (dual SSAO/MAO-B inhibitor) in REM sleep behaviour disorder look encouraging; Satistically significant⬇️in brain inflam. observed unilaterally in the putamen (p-value 0.0145) www.parkinsons.org.uk/news/2026/ne...

New research results indicate that serum changes in dopa decarboxylase, prolactin, & AOC3 primarily reflect treatment exposure rather than disease biology, highlighting the need to account for medication effects in proteomic studies (Go Ludo!) www.nature.com/articles/s41...

Researchers report inhibiting 15-PGDH restores redox homeostasis & confers neuroprotection in MODELS OF #Parkinsons www.sciencedirect.com/science/arti...

Interesting preprint manuscript: Researchers used network analysis to identify a specific sham surgery-related pattern in metabolic PET data from a double-blind #Parkinsons gene therapy trial; An imaging marker of placebo susceptibility in PD trials www.researchsquare.com/article/rs-1...

By analyzing #Parkinsons patients & LRRK2 gain-of-function mice, researchers proposed that PD represents an accelerated aging disorder driven by STING-dependent inflammation www.cell.com/cell-reports...

New research reveals 2 anatomically & functionally distinct populations of subthalamic nucleus neurons involved in levodopa-induced dyskinesia regulation, offering insights into the circuitry underlying subthalamic nucleus-deep-brain stimulation www.science.org/doi/10.1126/...

A #Parkinsons drug screen on induced pluripotent stem cells from a PARK9 patient carrying an ATP13A2 mutation identified 19 candidate compounds that reduced autophagosome accumulation (including paroxetine, Ro 25-6981, amisulpride, & PK11195) onlinelibrary.wiley.com/doi/10.1111/...

Multimodal neuroimaging (combining ¹⁸F-FPCIT dopamine transporter PET/MRI, quantitative susceptibility mapping, & diffusion MRI tractography) elucidates the posterior-to-anterior gradient of nigrostriatal degeneration in #Parkinsons (n=48 PD+10 controls) www.nature.com/articles/s41...

New research identifies lipid droplets as drivers of aberrant α-synuclein phase separation & suggest that lipid droplet-rich condensates contribute to mitochondrial dysfunction & impaired energy homeostasis link.springer.com/article/10.1...

Researchers have identified the bridge-like lipid transport protein VPS13C/PARK23 as a key component of a global early response pathway to lysosome damage; New insights into how loss-of-function mutations in VPS13C may enhance the risk of #Parkinsons www.nature.com/articles/s41...

The α-Synuclein aggregation landscape - new review provides a nutshell overview, from phase separation to neurotoxic intermediates febs.onlinelibrary.wiley.com/doi/10.1002/...

Interesting: Researchers previously screened an FDA approved compound library for TMEM175 modulators. Now, they present data on the most potent hit, candesartan cilexetil, with the cilexetil handle being the key pharmacophoric element journals.physiology.org/doi/abs/10.1...

"Convergent quantitative evidence points to a substantial vesicular storage defect in residual dopaminergic terminals in #Parkinsons". Findings challenges the sufficiency of nigrostriatal dopaminergic denervation alone to account for motor phenotype of PD www.neurology.org/doi/10.1212/...

Using longitudinal imaging data to model the progression of cardiac sympathetic & nigrostriatal dopaminergic degeneration, researchers use the resulting curves to estimate the prodromal period of Body-first Lewy body disease www.nature.com/articles/s41...

New data suggests that "air pollution may contribute to #Parkinsons through inflammation, oxidative stress, & mitochondrial dysfunction"; Serum samples collected from 616 PD patients & 271 controls in central California www.nature.com/articles/s41...

Could cerebrospinal fluid turnover dysfunction be a hidden early biomarker in REM sleep behavior disorder? New research indicates⬆️CSF & perivascular spaces volumes in iRBD without a matching increase in drainage venous structures; Impaired CSF filtration? www.nature.com/articles/s41...

"Distinct neuropsychological profiles & trajectories emerge in #Alzheimers & dementia with Lewy bodies depending on underlying pathology" - a retrospective longitudinal study of 350 individuals highlights trajectory differences www.neurology.org/doi/10.1212/...

Researchers report blood-based circular RNAs as possible biomarkers for early diagnosis of #Alzheimers; 34 circRNAs were comparable to plasma phosphorylated Tau-217 www.nature.com/articles/s41...